67 WALL STREET, New York - March 15, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act

Companies include: Atossa Genetics, Inc. (ATOS) and many more.

In the following excerpt from the Medical Devices Report, the CEO of Atossa Genetics, Inc. (ATOS) discusses company strategy and the outlook for this vital industry.

TWST: Let's start with a quick overview of Atossa Genetics and how you view the company at this point?

Dr. Quay: Atossa Genetics, the Breast Health Company, was founded in 2009. Our focus is on four laboratory tests, including two under development, that provide information to clinicians and patients about all aspects of breast health as well as a planned treatment program for early cancer using an intraductal microcatheter system.

TWST: Explain for us the mechanics of breast cancer diagnosis and detection through NAF? What are the typical fields of inquiry?

Dr. Quay: I think to frame that question, it's good to review where we are currently in the medical paradigm around breast cancer. The imaging techniques we use, mammography, ultrasound and MRI, are all based on using physics to measure changes in the breast and especially to identify cancer at a stage where it is big enough to be seen. That takes about one billion cells all in one spot.

At that point, the medical system's paradigm is do what some doctors call "cut, burn and poison," where a patient has a surgeon remove either the lump of cancer or the entire breast, a radiation therapist then passes X-rays into either the breast or the entire chest wall, and then an oncologist uses intravenous and oral chemotherapy to kill any cells that may have escaped the surgeon's knife or the X-rays and gotten into the body. That is the current paradigm.

It's unfortunate in that it doesn't work as well as we all would like it to work. We still have 235,000 women a year getting breast cancer. If you compare that to the situation with cervical cancer, where we've had an 80% reduction in cervical cancer...

Link:
Wall Street Transcript Interview with Steven Quay, CEO of Atossa Genetics , Inc. (ATOS)

Comments are closed.